Haku
Viitteet 1-5 / 5
2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays : Part 3 – LBA: immunogenicity, biomarkers and PK assays
(Future Science, 2017-12-05)
The 2017 11th Workshop on Recent Issues in Bioanalysis (11th WRIB) took place in Los Angeles/Universal City, California on 3–7 April 2017 with participation of close to 750 professionals from pharmaceutical/biopharmaceutical ...
2017 White Paper on recent issues in bioanalysis : A global perspective on immunogenicity guidelines & biomarker assay performance (Part 3-LBA: Immunogenicity, biomarkers and PK assays)
(Future Medicine, 2017)
The 2017 11th Workshop on Recent Issues in Bioanalysis took place in Los Angeles/Universal City, California, on 3-7 April 2017 with participation of close to 750 professionals from pharmaceutical/biopharmaceutical companies, ...
Interchangeability of Biosimilars : A European Perspective
(Springer International Publishing, 2017-04-01)
Many of the best-selling ‘blockbuster’ biological medicinal products are, or will soon be, facing competition from similar biological medicinal products (biosimilars) in the EU. Biosimilarity is based on the comparability ...
2017 White Paper on recent issues in bioanalysis: aren't BMV guidance/guidelines ‘Scientific’? : Part 1 – LCMS: small molecules, peptides and small molecule biomarkers
(Future Science, 2017-11-17)
The 2017 11th Workshop on Recent Issues in Bioanalysis (11th WRIB) took place in Los Angeles/Universal City, California on 3–7 April 2017 with participation of close to 750 professionals from pharmaceutical/biopharmaceutical ...
2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays : Part 2: hybrid LBA/LCMS biotherapeutics, biomarkers & immunogenicity assays and regulatory agencies’ inputs
(Future Science, 2017-12-05)
The 2017 11th Workshop on Recent Issues in Bioanalysis (11th WRIB) took place in Los Angeles/Universal City, California on 3–7 April 2017 with participation of close to 750 professionals from pharmaceutical/biopharmaceutical ...